NCT01715233View on ClinicalTrials.gov

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

April 30, 2017

Conditions
Metastatic Esophageal CancerGastroesophageal CancerGastric Cancer
Interventions
DRUG

Docetaxel

Modified Docetaxel 40mg/m2 on Day 1

DRUG

Leucovorin

Leucovorin 400mg/m2 on Day 1

DRUG

Fluorouracil

Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2

DRUG

Cisplatin

Cisplatin (or Carboplatin) 40mg/m2 on Day 3

Trial Locations (1)

21287

SKCCC at Johns Hopkins, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01715233 - Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | Biotech Hunter | Biotech Hunter